Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome
Interventions: Drug: Azacitidine; Drug: Trametinib; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions: Drug: Azacitidine; Drug: Trametinib; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
